Hadassah

Hadasit and Cellect Team Up for Stem Cell Innovation

Monday, Jan 30 2017

GvHD is a condition where the donor cells attack the recipient’s cells and destroy them, often causing damage to the recipient’s organs.

Cellect Biotechnology, an Israeli stem cell innovator, and Hadasit, the Hadassah Medical Organization’s technology transfer company, have signed an agreement to test the effectiveness in mice models of Cellect’s stem cell selection method for reducing a common complication of bone marrow transplants known as Graft versus Host disease (GvHD).

GvHD is a condition where the donor cells attack the recipient’s cells and destroy them, often causing damage to the recipient’s organs. Stem cell transplants contain a high ratio of mature cells, which can cause severe rejection symptoms, as well as morbidity and even death. The challenge is to separate stem cells effectively to achieve the critical mass of stem cell quantity and quality necessary for regenerative treatments with minimal rejection risk and at a reasonable cost that will make such treatments accessible for everyone.

Hadassah’s Prof. Amnon Peled, one of the world’s most renowned investigators of stem cells and natural killer cells, will be conducting a series of trials using Cellect’s ApoGraft method. In addition, Prof. Peled will investigate ApoGraft’s potential to induce “Graft versus Tumor” reaction, an immune response to a person's tumor cells by immune cells present in a donor's transplanted tissue. This induced reaction could lead to significant improvements in cancer treatment.

According to Cellect, the company has developed a transformative technology that enables any hospital, pharmaceutical company or research center to easily isolate large quantities of stem cells from any cellular mass to be readily available for stem cell-based treatments with negligible risks for rejection disease (GvHD) and at a fraction of the time and costs of today’s processes. “We are constantly advancing in providing vital medical and research data on the effectiveness of Cellect’s technology as the best solution for stem cell-based treatments,” says Shai Yarkoni, Cellect’s Co-Founder and Chief Executive Officer. “We are honored to be working with Prof. Peled and Hadassah to further demonstrate what our technology can contribute to the stem cell therapy arena.”

Amnon Peled notes: “Cellect’s ApoGraft may be one of the key tools for helping to fight a wide range of transplant and cancer related diseases using stem cells. We look forward to collaborating on this project and seeing its results.”

Related Stories

alt_text

Thursday, Oct 10 2019

Hadassah Leads International Study on Changing Intensive Care Practices on End-of-Life Decisions

Intensive care teams the world over deal daily with matters of life and death.

READ MORE ›
alt_text

Thursday, Oct 10 2019

Devastating Diagnosis, But Options for Optimism

A 26-year-old woman we can call Miriam is a wife and a mother, with a lively toddler. One recent day, she noticed a small lump in her breast.

READ MORE ›
alt_text

Tuesday, Oct 8 2019

From the Heart: Reflections Upon Retirement

Prof. Chaim Lotan has just completed two decades as director of Hadassah’s Heart Institute...

READ MORE ›
alt_text

Tuesday, Oct 8 2019

Intervening at the End of Life: What Has Changed?

On Yom Kippur, the Day of Atonement, as Jews the world over confront the uncertainty of their personal futures and chant the somber holiday prayer Unetaneh Tokef...

READ MORE ›
SUPPORT HADASSAH HOSPITALS

Learn more about the Hadassah Medical Organization.

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More